UNSPSC 51112518: Melphalan hydrochloride

This classification denotes a nitrogen mustard compound with the molecular formula C13H18Cl2N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1VXP4V453T, chemically known as l-phenylalanine, 4-(bis(2-chloroethyl)amino)- but more generally known as melphalan hydrochloride, which bears US NIH Compound Identifier 4053. Most nations, for tariff and trade purposes, schedule melphalan hydrochloride under HS 29224995 and SITC 51465. As of Q4 2014, MELPHALAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Melphalan hydrochloride bears US NLM identifiers UMLS ID C0771055 and NCI Concept Code C48002. SMILES: C1CC(CCC1C[C@@H](C(=O)O)N)N(CCCL)CCCL.CL.

UNSPSC 51112518 Melphalan hydrochloride is a Commodity code that designates a specific chemotherapy agent, but the recent state and local procurement activity tagged under it does not reflect direct purchase of the drug itself. Instead, the Texas Health and Human Services Commission (HHS) posted an RFI in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program — an exploratory procurement mechanism designed to gather market intelligence on how vendors and manufacturers can establish direct relationships with state pharmacy benefit programs to improve prescription fulfillment and cost management. The RFI solicits information from vendors about their capacity to enter direct contracts with self-insured health plans and state agencies outside of traditional pharmacy benefit manager, group purchasing organization, and wholesaler arrangements, with emphasis on experience in negotiated net pricing models and outcomes-based agreements.

The single recent opportunity under this code is the Texas HHS RFI (No. HHS0017013), posted April 3, 2026, with a response deadline of April 3, 2026. The RFI functions as a preliminary information-gathering phase rather than a formal competitive solicitation, with no award value, budget range, set-asides, or binding timeline specified. Texas HHS indicates it will use vendor responses to inform future formal procurement strategy, contracting approach, and program design before issuing a subsequent RFP with established financial and temporal parameters. The code shows limited recent relevant activity; if your firm pursues pharmaceutical supply or manufacturer-direct contracting relationships with state health agencies, this emerging TPI initiative signals potential future opportunities in Texas and possibly other states adopting similar direct-to-manufacturer pharmacy models, though formal competitive solicitations have not yet been posted.